2 assets in Undifferentiated Carcinoma Of Esophagus

Therapeutic assets addressing Undifferentiated Carcinoma Of Esophagus, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Undifferentiated Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Undifferentiated Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)